Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Drugs giant struggling to manage slump in demand for Covid vaccines and antivirals as it falls behind rivals on obesity ...
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
I.C. Stars has started a new, unique program in partnership with a nonprofit to help new mothers start careers in information ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback